GR3017218T3 - Vaccine against group B Neisseria meningitidis, gammaglobulin and transfer factor. - Google Patents

Vaccine against group B Neisseria meningitidis, gammaglobulin and transfer factor.

Info

Publication number
GR3017218T3
GR3017218T3 GR950402324T GR950402324T GR3017218T3 GR 3017218 T3 GR3017218 T3 GR 3017218T3 GR 950402324 T GR950402324 T GR 950402324T GR 950402324 T GR950402324 T GR 950402324T GR 3017218 T3 GR3017218 T3 GR 3017218T3
Authority
GR
Greece
Prior art keywords
protein
treatment
chromatography
mixture
neisseria meningitidis
Prior art date
Application number
GR950402324T
Other languages
Greek (el)
English (en)
Inventor
Huergo Concepcion Campa
Gonzalez Victoriano Gus Sierra
Vazquez Maria Merced Gutierrez
Jorrin Gonzalo Bisset
Imia Luis Guillermo Garcia
Rizo Gisela De La Cari Puentes
Herrera Maria Del Car Sampedro
Padron Franklin Sotolongo
Le Riverend Morales El Xochitl
Dominguez Manuel Alfr Galguera
Original Assignee
Nacional De Biopreparados Cent
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nacional De Biopreparados Cent filed Critical Nacional De Biopreparados Cent
Publication of GR3017218T3 publication Critical patent/GR3017218T3/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria
    • C07K16/1217—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-negative bacteria from Neisseriaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
GR950402324T 1987-07-30 1995-08-24 Vaccine against group B Neisseria meningitidis, gammaglobulin and transfer factor. GR3017218T3 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU1987125 1987-07-30

Publications (1)

Publication Number Publication Date
GR3017218T3 true GR3017218T3 (en) 1995-11-30

Family

ID=5459411

Family Applications (1)

Application Number Title Priority Date Filing Date
GR950402324T GR3017218T3 (en) 1987-07-30 1995-08-24 Vaccine against group B Neisseria meningitidis, gammaglobulin and transfer factor.

Country Status (11)

Country Link
US (2) US5597572A (enEXAMPLES)
EP (1) EP0301992B1 (enEXAMPLES)
JP (1) JPH01125328A (enEXAMPLES)
AT (1) ATE122893T1 (enEXAMPLES)
AU (3) AU615461B2 (enEXAMPLES)
CA (1) CA1341199C (enEXAMPLES)
DE (1) DE3853854T2 (enEXAMPLES)
ES (1) ES2074445T3 (enEXAMPLES)
GR (1) GR3017218T3 (enEXAMPLES)
IN (1) IN167607B (enEXAMPLES)
RU (1) RU2023448C1 (enEXAMPLES)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7118757B1 (en) 1988-12-19 2006-10-10 Wyeth Holdings Corporation Meningococcal class 1 outer-membrane protein vaccine
ATE120093T1 (de) * 1988-12-19 1995-04-15 Praxis Biolog Inc Meningococcales klasse i-aussenmembranprotein- vakzin.
CU22302A1 (es) * 1990-09-07 1995-01-31 Cigb Secuencia nucleotidica codificante para una proteina de la membrana externa de neisseria meningitidis y uso de dicha proteina en preparados vacunales
ATE190502T1 (de) * 1993-05-13 2000-04-15 American Cyanamid Co Herstellung und verwendungen von los-verminderten aussenmembran-proteinen von gram-negativen kokken
US6287574B1 (en) 1995-03-17 2001-09-11 Biochem Pharma Inc. Proteinase K resistant surface protein of neisseria meningitidis
IL123720A (en) * 1995-09-18 2002-02-10 Us Army Medical Res Material C Methods for the creation of immune subunits of proteasomes that are multivolent and non-covalently linked
FR2751000B1 (fr) * 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
US6558677B2 (en) * 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
RU2347813C2 (ru) * 1997-11-06 2009-02-27 Чирон С.П.А. Антигены нейссерий
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
GB9808734D0 (en) * 1998-04-23 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9808866D0 (en) * 1998-04-24 1998-06-24 Smithkline Beecham Biolog Novel compounds
GB9810276D0 (en) * 1998-05-13 1998-07-15 Smithkline Beecham Biolog Novel compounds
GB9811260D0 (en) 1998-05-26 1998-07-22 Smithkline Beecham Biolog Novel compounds
US10967045B2 (en) 1998-11-02 2021-04-06 Secretary of State for Health and Social Care Multicomponent meningococcal vaccine
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
WO2000043517A1 (en) * 1999-01-22 2000-07-27 Smithkline Beecham Biologicals S.A. Basb055 polynucleotide and polypeptide from neisseria meningitidis. uses thereof
NZ528254A (en) 1999-05-19 2005-07-29 Chiron S Combined neisserial compositions
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
GB9929923D0 (en) * 1999-12-17 2000-02-09 Baldwin Thomas J Antigen preparations
KR20030024811A (ko) * 2000-07-27 2003-03-26 칠드런즈 하스피틀 앤드 리써치 센터 앳 오클랜드 나이세리아 메닌지티디스에 의하여 유발되는 질병에 대한광범위하게 유효한 보호를 위한 백신
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
RU2355704C2 (ru) * 2001-04-17 2009-05-20 Новартис Вэксинс Энд Диагностикс, Инк Моноклональное антитело, направленное против gna33 пептида, и его применение
CN1306956C (zh) * 2001-04-17 2007-03-28 希龙公司 诱导功能活性抗体的脑膜炎球菌b抗原表位的分子模拟物
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
IL145926A0 (en) 2001-10-15 2002-07-25 Mor Research Applic Ltd Peptide epitopes of mimotopes useful in immunomodulation
CU22983A1 (es) * 2002-05-08 2004-09-09 Inst Finlay Composición vacunal contra las alergias y método para su obtención y empleo en el tratamiento de las mismas
US20040096461A1 (en) * 2002-07-30 2004-05-20 Baxter Healthcare Corporation Chimeric multivalent polysaccharide conjugate vaccines
NZ537181A (en) 2002-08-02 2007-01-26 Glaxosmithkline Biolog S Vaccine composition comprising transferrin binding protein and Hsf from gram negative bacteria
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ATE466875T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
CU23313A1 (es) 2002-11-27 2008-09-25 Inst Finlay Ct De Investigacia Mã0/00todo de obtenciã"n de estructuras cocleares. composiciones vacunales y adyuvantes basados en estructuras cocleares y sus intermediarios
CA3042073C (en) 2003-01-30 2022-09-13 Novartis Vaccines And Diagnostics S.R.L. Injectable vaccines against multiple meningococcal serogroups
US20040241190A1 (en) * 2003-04-07 2004-12-02 Xenova Research Limited Vaccine preparations
RU2250113C2 (ru) * 2003-06-04 2005-04-20 Институт биоорганической химии им. академиков М.М.Шемякина и Ю.А.Овчинникова Российской академии наук Способ приготовления бивалентной вакцины для профилактики менингококковой инфекции
GB0316560D0 (en) * 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0323103D0 (en) 2003-10-02 2003-11-05 Chiron Srl De-acetylated saccharides
CU23420A1 (es) * 2003-12-30 2009-09-08 Univ De Cambridge Proteoliposomas y sus derivados como adyuvantes inductores de respuesta citotóxica y las formulaciones resultantes
GB0406013D0 (en) 2004-03-17 2004-04-21 Chiron Srl Analysis of saccharide vaccines without interference
GB0408977D0 (en) 2004-04-22 2004-05-26 Chiron Srl Immunising against meningococcal serogroup Y using proteins
GB0411387D0 (en) 2004-05-21 2004-06-23 Chiron Srl Analysis of saccharide length
GB0413868D0 (en) 2004-06-21 2004-07-21 Chiron Srl Dimensional anlaysis of saccharide conjugates
GB0416120D0 (en) 2004-07-19 2004-08-18 Health Prot Agency Stable compositions containing OMV's
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
EP1855715B1 (en) 2005-01-27 2013-03-13 Children's Hospital & Research Center at Oakland Gna1870-based vesicle vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
US9789179B2 (en) 2005-06-27 2017-10-17 Glaxosmithkline Biologicals S.A. Immunogenic composition
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
GB0605757D0 (en) 2006-03-22 2006-05-03 Chiron Srl Separation of conjugated and unconjugated components
US7943352B2 (en) * 2006-03-29 2011-05-17 Bacoustics, Llc Apparatus and methods for vaccine development using ultrasound technology
US8414899B2 (en) 2006-04-11 2013-04-09 Yeda Research And Development Co. Ltd. Vaccines comprising multimeric HSP60 peptide carriers
EA200970731A1 (ru) * 2007-02-07 2010-02-26 Сигма-Тау Индустрие Фармасьютике Риуните С.П.А. Рекомбинантные антигены цитомегаловируса человека (hcmv)
AU2009215364B2 (en) * 2008-02-21 2014-09-18 Glaxosmithkline Biologicals S.A. Meningococcal fHBP polypeptides
CU20080215A7 (es) 2008-11-19 2012-06-21 Inst Finlay Vacunas unitemporales
CN104650241A (zh) 2009-08-27 2015-05-27 诺华股份有限公司 包括脑膜炎球菌fHBP序列的杂交多肽
CA2779816A1 (en) 2009-10-27 2011-05-05 Novartis Ag Modified meningococcal fhbp polypeptides
CA2792687A1 (en) 2010-03-10 2011-09-15 Glaxosmithkline Biologicals S.A. Immunogenic composition
CU20100083A7 (es) 2010-05-05 2012-06-21 Inst Finlay Tolerogenos adyuvados como vacuna de malaria
CN107913396B (zh) 2010-08-23 2022-03-08 惠氏有限责任公司 脑膜炎萘瑟氏菌rLP2086抗原的稳定制剂
GB201015132D0 (en) 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
SG187912A1 (en) 2010-09-10 2013-04-30 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
CU20110202A7 (es) * 2011-11-02 2013-12-27 Inst Finlay Ct De Investigación Producción De Sueros Y Vacunas Composición inmunogénica de polisacáridos planos adyuvados y las formulaciones resultantes
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
KR101763625B1 (ko) 2012-03-09 2017-08-01 화이자 인코포레이티드 수막염균 조성물 및 이의 사용 방법
EP2689775A1 (en) 2012-07-25 2014-01-29 Instituto Finlay, Centro de Investigacion-Produccion de vacunas y sueros Cochleate with only one mamp
CA2903716C (en) 2013-03-08 2019-04-09 Pfizer Inc. Immunogenic fusion polypeptides
AU2014316722B2 (en) 2013-09-08 2017-09-07 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
HRP20202080T1 (hr) 2014-02-28 2021-02-19 Glaxosmithkline Biologicals Sa Modificirani meningokokni fhbp polipeptidi
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
KR102567845B1 (ko) 2017-01-31 2023-08-17 화이자 인코포레이티드 네이세리아 메닌기티디스 조성물 및 그의 방법
RU2659948C1 (ru) * 2017-03-14 2018-07-04 Федеральное государственное бюджетное научноеучреждение "Омский аграрный научный центр" (ФГБНУ "Омский АНЦ") Способ получения R-бруцеллёзной сыворотки на кроликах
CN110157767A (zh) * 2019-04-18 2019-08-23 金花企业(集团)股份有限公司 一种转移因子口服溶液生物活性测定方法
CA3155669A1 (en) 2019-09-27 2021-04-01 Pfizer Inc. Neisseria meningitidis compositions and methods thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4271147A (en) * 1980-01-10 1981-06-02 Behringwerke Aktiengesellschaft Process for the isolation of membrane proteins from Neisseria meningitidis and vaccines containing same
US4386066A (en) * 1981-08-20 1983-05-31 Merck & Co., Inc. Immunogenic complex from N. gonorrhoeae
US4451446A (en) * 1982-03-04 1984-05-29 Smithkline-Rit Process for the preparation of polysaccharide-protein complexes from bacterial capsules, obtained products and immunogenic compositions containing them
US4885005A (en) * 1982-11-12 1989-12-05 Baxter International Inc. Surfactant treatment of implantable biological tissue to inhibit calcification
EP0109688A3 (en) * 1982-11-23 1986-12-03 The Wellcome Foundation Limited Improved complexes, processes for obtaining them and formulations containing such complexes
US4505853A (en) * 1983-11-18 1985-03-19 Ortho Pharmaceutical Corporation Enzyme-resistant immunomodulatory peptides
US4547489A (en) * 1984-06-11 1985-10-15 Ortho Pharmaceutical Corporation Conformationally restricted thymopentin-like compounds
US4629723A (en) * 1984-06-27 1986-12-16 Ortho Pharmaceutical Corporation Potent thymopentin analogs
US4601903A (en) * 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US4786592A (en) * 1986-06-18 1988-11-22 Scripps Clinic And Research Foundation Neisseria gonorrhoeae lectin useful as a vaccine and diagnostic marker and means for producing this lectin
US4838888A (en) * 1987-04-17 1989-06-13 Baxter Travenol Laboratories, Inc. Calcification mitigation of implantable bioprostheses

Also Published As

Publication number Publication date
ES2074445T3 (es) 1995-09-16
IN167607B (enEXAMPLES) 1990-11-24
AU5319794A (en) 1994-03-24
US5747653A (en) 1998-05-05
DE3853854T2 (de) 1996-02-08
ATE122893T1 (de) 1995-06-15
AU8134991A (en) 1991-10-31
AU2031288A (en) 1989-05-25
US5597572A (en) 1997-01-28
RU2023448C1 (ru) 1994-11-30
CA1341199C (en) 2001-03-06
DE3853854D1 (de) 1995-06-29
AU615461B2 (en) 1991-10-03
JPH01125328A (ja) 1989-05-17
EP0301992A2 (en) 1989-02-01
EP0301992B1 (en) 1995-05-24
EP0301992A3 (en) 1990-02-14

Similar Documents

Publication Publication Date Title
EP0301992A3 (en) Vaccine against group B Neisseria meningitidis, gammaglobulin and transfer factor.
Une et al. Roles of V antigen in promoting virulence and immunity in yersiniae.
FI104539B (fi) Menetelmä muunnellun Neisseria meningitidis ryhmä B polysakkaridin tai muunnellun E. coli K1 kotelomaisen polysakkaridin valmistamiseksi
US5811102A (en) Modified meningococcal polysaccharide conjugate vaccines
LV12309A (lv) Pneimokoku polisaharidus saturosa vakcina
ATE130032T1 (de) Verfahren zum verringern der toxizität von lps und verfahren zum dezoxifizieren eines lps- haltigen flüssigen therapeutischen mittels.
DE68924162D1 (de) Stressproteine und verwendungen dafür.
JPH05246890A (ja) グラム陰性菌トキソイドにより得られる免疫グロブリン
NZ299249A (en) Use of an antigenic conjugate of a capsular polysaccharide from streptococcus and a protein component to immunise neonates
WO1996012020A3 (en) Hemoglobin receptors from neisseriae
Jarrett et al. Antibody response and virus survival in cats vaccinated against feline leukaemia
JPH01502190A (ja) インフルエンザ菌用ワクチンおよび診断法
DE69031351D1 (de) Zubereitungen und behandlungen von pneumonia in tieren
USRE37741E1 (en) Purified nontypable Haemophilus influenzae P5 protein as a vaccine for nontypable Haemophilus influenzae infection
JPH01190635A (ja) 抗体およびそれを有効成分とするう蝕予防剤、並びにこれらの製造方法
US6165468A (en) Antigenic carbohydrate linked to an immunogenic carrier
EP0400569B1 (en) Method for preparing a vaccine from Streptococcus mutans for dental caries and vaccinal compositions for dental caries used as nasal drops
ATE118982T1 (de) Verfahren zur herstellung von transparenten milchmolkeproteinen und milchmolkeproteinprodukte.
JP3135060B2 (ja) ヘモフィルスインフルエンザｂ型菌の外皮膜タンパク質Ｐ２の部分断片を用いた接合体
Reed Chemical and antigenic properties of the cell wall of Actinomyces viscosus (Strain T6)
US3968202A (en) Tetanus antigen and process for its manufacture
Gilbert et al. Purification of type 5 capsular polysaccharide from Straphylococcus aureus by a simple efficient method
US6248563B1 (en) Chlamydia trachomatis serotype D genes
PT87001A (pt) Processo para a preparacao de uma vacina contra a disenteria suina e fins analogos
PT85248A (fr) Procede d:isolement d:un peptide presentant des proprietes antigeniques isole de la proteine 28kd de ?s.mansoni?,anticorps monoclonaux reconnaissant au moins un epitope dudit peptide et applications de celui-ci dans l:induction de la synthese d:anticorps neutralisants